Seneca Biopharma Inc(SNCA)stock report

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Finance:
Market Cap:5.4M; Shares Outstanding:3.9M; Short Interest: 1.18%; Q3 2019(9/30/19): Cash 7.3M. Loss 6.31M

EPS and Sales:
https://finance.yahoo.com/quote/SNCA/financials?p=SNCA

Date EPS % last year % last quarter
2018.9.30 -4.8 / /
2019.9.30 -6.08 21.05% -26.67%

 

Date Sales % last year % last quarter
2018.9.30 0.26M / /
2019.9.30 0.01M -94.99% -96.15%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=SNCA&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/SNCA/institutional-ownership/

2020.01.09:
Total institutions: 31,no change
Shares hold: 474.7k shares. no change
shares% hold: 12.28%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/SNCA/price-targe

Leave a Reply